ICH aims to slash number of drugs needing 2-year rodent carcinogenicity testing
This article was originally published in SRA
Executive Summary
The International Conference on Harmonisation has approved plans for developing a new guideline on rodent carcinogenicity testing of human drugs1. The document, when finalised and adopted, could result in fewer drugs requiring two-year rodent carcinogenicity studies in cases where other data is available to support patient safety.